Description
CYC116 is an orally active small molecule multi-kinase inhibitor with antineoplastic activity. CYC116 inhibits Aurora kinases A and B and vascular endothelial growth factor receptor 2 (VEGFR2), resulting in disruption of the cell cycle, rapid cell death.
Abbr
CYC-116(AURKA, AURKB, KDR)
Alias
RP5-1167H4.6, AIK, ARK1, AURA, AURORA2, BTAK, PPP1R47, STK15, STK6, STK7
Product Overview
Inhibits Aurora kinases A and B and vascular endothelial growth factor receptor 2 (VEGFR2)
Stability
2 years -20 centigrade Powder
1 month -4 centigrade in DMSO
More than one month -80 centigrade in DMSO
Synonyms
RP5-1167H4.6, AIK, ARK1, AURA, AURORA2, BTAK, PPP1R47, STK15, STK6, STK7
Targets
Aurora kinases A, Aurora kinases B, vascular endothelial growth factor receptor 2 (VEGFR2)
Molecular Formula
C18H20N6OS
Chemical Name
4-(2-amino-4-methylthiazol-5-yl)-N-(4-morpholinophenyl)pyrimidin-2-amine
Solubility
DMSO > 112mg/mL Water >1mg/mL Ethanol > 4mg/mL
Download Datasheet